---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004639"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:43:47.203440+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports Q4 2022 net loss of $78.1M; cash $957.9M; VAX-24 infant IND cleared

## Summary
- Net loss of $78.1M for Q4 2022 and $223.5M for full year 2022; R&D expenses $51.6M and $169.5M respectively.
- Cash, cash equivalents and investments $957.9M as of Dec 31, 2022, up from $273.1M a year ago.
- FDA cleared VAX-24 infant IND; Phase 2 infant study to start Q2 2023; Breakthrough Therapy designation for adults.
- Positive Phase 1/2 data for VAX-24 in adults 18-64; Phase 2 study in adults 65+ enrollment completed; topline data expected Q2 2023.
- Raised ~$805M in gross proceeds from two follow-on equity offerings in 2022; VAX-31 adult IND expected H2 2023.

## SEC filing metadata
- accession: 0000950170-23-004639
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000095017023004639/0000950170-23-004639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000095017023004639/pcvx-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004639
- JSON: https://secwatch.observer/filing/0000950170-23-004639.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004639.txt

## Key facts
- Earnings Releases
  Vaxcyte, Inc. reported financial results for the quarter and full year ended December 31, 2022.
  - Period: the quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On February 27, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000095017023004639/0000950170-23-004639-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.